Quantitative assessment of residual tumor is a strong and independent predictor of survival in methylated glioblastoma following radiochemotherapy with CCNU/TMZ

Lymphoma

Total Metabolic Tumor Volume Is a Strong Independent Prognostic Factor in Follicular Lymphomas: Results From a Sub-Study of the FOLL12 Trial

Am J Hematol

Durmo R, Chauvie S, Minoia C, Bergesio F, Fallanca F, Peano S, Marcheselli L, Anastasia A, Boccomini C, Corradini P, Olivieri J, Arcaini L, Cavallo F, Ibatici A, Nassi L, Tarantino V, Pinto A, Stelitano C, Pulsoni A, Ricci F, Mancuso S, Cencini E, Di Renzo N, Mannarella C, Palmas A, Zinzani P, Bocci C, Rossi F, Carella AM, Federico M, Versari A, Guerra L, Luminari S

doi: 10.1002/ajh.27711

CHICAGO 2025

Genitourinary Cancer

ENZA-p: PSMA tumor volume predicts survival benefit from adding Lu-PSMA-617 to enzalutamide in high-volume, high-risk mCRPC

Genitourinary Cancer

Oncologic outcomes of retroperitoneal lymph node dissection following first-line chemotherapy for metastatic non-seminomatous germ cell tumors

Ann Oncol

Matulewicz RS, Baky F, Liso N, Williams BM, Porwal S, Assel M, Carver BS, Bajorin DF, Motzer RJ, Bosl GJ, McHugh DJ, Reuter VE, Tickoo SK, Al-Ahmadie H, Vickers AJ, Funt SA, Feldman DR, Sheinfeld J

doi: 10.1016/j.annonc.2025.03.002

Central Nervous System Tumors

High peritumoral network connectedness in glioblastoma reveals a distinct epigenetic signature and is associated with decreased overall survival

Neuro Oncol

Jütten K, Ort J, Kernbach JM, Meyer-Baese A, Meyer-Baese U, Hamou HA, Clusmann H, Wiesmann M, Bremer J, Koch H, Bak A, Ricklefs F, Drexler R, Heiland DH, Delev D

doi: 10.1093/neuonc/noaf101

Multiple Myeloma (MM)

Minimal Residual Disease-Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials

J Clin Oncol

Shi Q, Paiva B, Pederson LD, Dimier N, Talpes E, Prior TJ, Orfao A, Moreau P, Sonneveld P, Kumar SK, Dixon JG, Patel R, Bartlett BJ, Schecter J, McCarthy P, Hose D, Seckinger A, Mattia D, Goldschmidt H, Oliva S, Owen RG, Anderson KC, San-Miguel J, Durie BGM, Munshi N, International Independent Team for Endpoint Approval of Myeloma Minimal Residual Disease (i2TEAMM) Group

doi: 10.1200/JCO-24-02020

COMMENTED

Genitourinary CancerNuclear Medicine

Quantitative ⁶⁸Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following ¹⁷⁷Lu-PSMA-617 (VISION Trial)

★ 2 Recommended and commented by Prof. Dr Ken Herrmann, Faculty Member

Radiology

Kuo PH, Morris MJ, Hesterman J, Kendi AT, Rahbar K, Wei XX, Fang B, Adra N, Garje R, Michalski JM, Chi K, de Bono J, Fizazi K, Krause B, Sartor O, Tagawa ST, Ghebremariam S, Brackman M, Wong CC, Catafau AM, Benson T, Armstrong AJ, Herrmann K

doi: 10.1148/radiol.233460

Central Nervous System Tumors

Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma

J Clin Oncol

Kacimi SEO, Dehais C, Feuvret L, Chinot O, Carpentier C, Bronnimann C, Vauleon E, Djelad A, Cohen-Jonathan Moyal E, Langlois O, Campone M, Ducloie M, Noel G, Cuzzubbo S, Taillandier L, Ramirez C, Younan N, Menei P, Dhermain F, Desenclos C, Ghiringhelli F, Bourg V, Ricard D, Faillot T, Appay R, Tabouret E, Nichelli L, Mathon B, Thomas A, Tran S, Bielle F, Alentorn A, Iorgulescu JB, Boëlle PY, Labreche K, Hoang-Xuan K, Sanson M, Idbaih A, Figarella-Branger D, Ducray F, Touat M, POLA Network

doi: 10.1200/JCO.24.00049

Central Nervous System Tumors

Automated longitudinal treatment response assessment of brain tumors: a systematic review

Neuro Oncol

Shi T, Kujawa A, Linares C, Vercauteren T, Booth TC

doi: 10.1093/neuonc/noaf037

Gastrointestinal Cancer

A tumor-naive ctDNA assay detects minimal residual disease in resected stage II or III colorectal cancer and predicts recurrence: subset analysis from the GALAXY study in CIRCULATE-Japan

Clin Cancer Res

Nakamura Y, Kaneva K, Lo C, Neems D, Freaney JE, Boulos H, Hyun SW, Islam F, Yamada-Hanff J, Driessen TM, Sonnenschein A, DeSantis DF, Kotani D, Watanabe J, Kotaka M, Mishima S, Bando H, Yamazaki K, Taniguchi H, Takemasa I, Kato T, Sangli C, Tell R, Blidner R, Yoshino T, Sasser K, Oki E, Nimeiri H

doi: 10.1158/1078-0432.CCR-24-2396

Related content

Total Metabolic Tumor Volume Is a Strong Independent Prognostic Factor in Follicular Lymphomas: Results From a Sub-Study of the FOLL12 Trial

ENZA-p: PSMA tumor volume predicts survival benefit from adding Lu-PSMA-617 to enzalutamide in high-volume, high-risk mCRPC

Oncologic outcomes of retroperitoneal lymph node dissection following first-line chemotherapy for metastatic non-seminomatous germ cell tumors

High peritumoral network connectedness in glioblastoma reveals a distinct epigenetic signature and is associated with decreased overall survival

Minimal Residual Disease-Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials

Quantitative 68Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177Lu-PSMA-617 (VISION Trial)

Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma

Automated longitudinal treatment response assessment of brain tumors: a systematic review

A tumor-naive ctDNA assay detects minimal residual disease in resected stage II or III colorectal cancer and predicts recurrence: subset analysis from the GALAXY study in CIRCULATE-Japan

Quantitative ⁶⁸Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following ¹⁷⁷Lu-PSMA-617 (VISION Trial)